Skip to content
value.today

CorMedix Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

No three-year revenue growth on file: 5% to start with.

%

US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt or cash not on file: 0 to start with.

What today's price assumes

A market value of $652 M means free cash flow growing 9.7% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.

Cash-flow value of the shares
$460 M
-29% against the market value
Value of the whole business
$460 M
before net debt
Value from after year 10
53%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →0%2.5%5%7.5%10%
7.92%-34%-19%-2%+19%+45%
8.92%-44%-32%-18%-1%+20%
9.92%-51%-41%-29%-15%+2%
10.92%-56%-48%-38%-26%-12%
11.92%-61%-54%-45%-35%-22%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Biotechnology: $1.5 B to $9.6 B, median $3.3 BPrice to salesPrice to sales of Biotechnology: $701 M to $3.2 B, median $1.6 BPrice to bookPrice to book of Biotechnology: $1.3 B to $5.2 B, median $1.9 BCash-flow value$0 M$2.6 B$5.2 B$7.8 B$10.4 BMarket value $652 M

Your own DCF model

A full discounted-cash-flow model of CorMedix Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times CorMedix Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)CorMedix Inc.Applied toValue (25th to 75th)Companies
P/E9.4× / 20.3× / 59.0×10.2×net income $163 M$1.5 B to $9.6 B33
Price to sales2.3× / 5.0× / 10.2×1.6×revenue $312 M$701 M to $3.2 B84
Price to book3.2× / 4.6× / 12.9×1.6×book equity $405 M$1.3 B to $5.2 B69

Against its own history

CorMedix Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

3.5×

Now below its median of 3.8×; range 3.1× to 56.8× over 18 months.

0×14×28×43×57×2026P/E 3×Median 4×

Price to sales

1.4×

Now below its median of 1.8×, in the bottom quarter of its range; range 1.3× to 894.7× over 15 months.

0×224×447×671×895×2020202120222023202420252026Price to sales 1×Median 2×

Price to book

1.6×

Now below its median of 7.2×, in the bottom quarter of its range; range 1.3× to 36.5× over 30 months.

0×9×18×27×37×2020202120222023202420252026Price to book 2×Median 7×

As of Oct 29, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$312 M$163 M$175 M$2 M$173 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$43 M$-18 M$-51 M$0 M$-51 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023—$-46 M$-38 M$0 M$-39 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$0 M$-30 M$-24 M$0 M$-25 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$0 M$-28 M$-21 M$1 M$-23 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$0 M$-22 M$-22 M$0 M$-22 M—SEC annual report (10-K, 20-F)